ESCAPE-NA1: Safety and Efficacy of NA-1 in Subjects Undergoing Endovascular Thrombectomy for Stroke

To determine the efficacy of the neuroportectant, NA-1, in reducing the global disability in subjects with major acute ischemic stroke (AIS).

Bio

There is extensive preclinical evidence that neuroprotection is of greatest benefit for improving functional outcome in studies employing experimental animal stroke models in which stroke is followed by reperfusion, as compared with stroke models in which arterial vessel occlusion is undertaken without reperfusion.

ESCAPE-NA1 is a Phase 3, randomized, placebo vs. drug study to determine the efficacy of the neuroprotectant drug NA-1, in reducing global disability in patients experiencing a major ischemic stroke. Subjects having acute ischemic stroke , who are selected for endovascular revascularization will be given a single dose of NA-1or placebo as soon as they are deemed to have met the enrollment criteria.

Principal Investigator: Donald Frei, MD

For more information about this trial, please contact Alicia Drew, Director, Research and Physician Services at Radiology Imaging Associates.

If you would like to explore more clinical information about this trial, please see the trial page on ClinicalTrials.gov